Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.532
Ask: 1.58
Change: 0.008 (0.52%)
Spread: 0.048 (3.133%)
Open: 1.53
High: 1.55
Low: 1.53
Prev. Close: 1.548
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CDX Option Update

14 Apr 2021 07:00

RNS Number : 3698V
Hemogenyx Pharmaceuticals PLC
14 April 2021
 

14 April 2021

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

CDX Option Update

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces an update on negotiations regarding the future development of its leading product candidate CDX bispecific antibody ("CDX") for the treatment of acute myeloid leukemia ("AML") and other potential applications.

 

On 13 January 2021, the Company announced the completion of the development of CDX with a global pharmaceutical company ("GlobalCo"). With the original development phase of the agreement completed, GlobalCo or the Company would exercise an option to license the other party's intellectual property necessary to exploit the CDX antibody. On 1 April 2021, the Company announced that negotiations regarding the licensing and development of CDX had commenced, and that the results of those negotiations will be announced upon their completion.

 

The Company has now received notice from GlobalCo that it will not exercise its option to license the Company's intellectual property. Accordingly, the Company has given notice to GlobalCo of its intention to exercise its own option to license GlobalCo's intellectual property on an exclusive, worldwide basis. The Company continues to work actively with GlobalCo in relation to development of the antibody, and to negotiate with GlobalCo to determine the exact terms of the licence and GlobalCo's continued involvement in the progression of CDX toward clinical trials. Further announcements will be made in due course.

 

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: 

"We are pleased with the progress of our negotiations with GlobalCo and their continued interest in working with Hemogenyx Pharmaceuticals. We look forward to advancing our CDX antibody to clinical trials."

 

About AML

 

AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation No 596/2014 until the release of this announcement. 

 

Enquiries:

 

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

 

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

 

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDMZGMDMFGGMZZ
Date   Source Headline
12th Jun 20197:00 amRNSCDX Effective as Conditioning Therapeutic in vivo
5th Jun 20198:15 amRNSCDX Antibody is Effective against AML in vivo
30th May 20194:40 pmRNSSecond Price Monitoring Extn
30th May 20194:35 pmRNSPrice Monitoring Extension
30th May 20197:00 amRNSCDX Antibody is Effective against ALL in vitro
28th May 20197:00 amRNSPosting of Annual Report and Notice of AGM
15th May 20197:00 amRNSVariation of Terms of Warrant Instrument
1st May 20197:00 amRNSDirector/PDMR Shareholding
29th Apr 20193:10 pmRNSFinal Results for the Year Ended 31 December 2018
30th Jan 20197:00 amRNSPresentation at Cancer Immunotherapy Conference
7th Jan 20197:00 amRNSOperations Update
20th Dec 20187:00 amRNSDirectorate Change
5th Nov 20187:00 amRNSDirectorate Change & Appointment
22nd Oct 20187:00 amRNSOrgenesis collaboration for Hu-PHEC development
19th Oct 20187:00 amRNSCollaboration, License and Investment by Orgenesis
15th Oct 20187:00 amRNSCollaboration with Johnson & Johnson Innovation
28th Sep 20189:30 amRNSHalf-year Report
28th Sep 20187:00 amRNSChange of Adviser
3rd Sep 20187:00 amRNSHemogenyx to present at Oxford conference
27th Jun 201811:39 amRNSResult of AGM
8th Jun 20187:00 amRNSInvestor presentation
5th Jun 20186:05 pmRNSPosting of Annual Report & Notice of AGM
14th May 20187:00 amRNSDevelopment Agreement
8th May 20187:00 amRNSResearch Collaboration with Rockefeller University
30th Apr 20184:23 pmRNSFinal Results
11th Apr 20185:15 pmRNSDirector/PDMR Shareholding
3rd Apr 20187:00 amRNSDirectorate Change
14th Mar 201811:05 amRNSSecond Price Monitoring Extn
14th Mar 201811:00 amRNSPrice Monitoring Extension
13th Mar 20187:00 amRNSCollaboration with major US biotechnology company
6th Mar 20187:00 amRNSAdvisory Board Appointment
1st Mar 20187:00 amRNSAlign Research Initiation of Coverage
27th Feb 20184:40 pmRNSSecond Price Monitoring Extn
27th Feb 20184:35 pmRNSPrice Monitoring Extension
26th Feb 20182:17 pmRNSStmnt re Share Price Movement
12th Feb 20187:00 amRNSDirector/PDMR Shareholding
7th Feb 20187:00 amRNSDirector/PDMR Shareholding
11th Jan 20187:00 amRNSHemogenyx Welcomes N.Y. Lt. Governor to its Labs
7th Dec 201712:16 pmRNSResult of AGM
7th Dec 20177:00 amRNSAGM Statement
20th Nov 20177:00 amRNSUniversity of Oxford Collaboration
15th Nov 20177:00 amRNSDirectorate Change
14th Nov 20177:00 amRNSNotice of AGM
13th Nov 20174:40 pmRNSSecond Price Monitoring Extn
13th Nov 20174:35 pmRNSPrice Monitoring Extension
13th Nov 20172:05 pmRNSSecond Price Monitoring Extn
13th Nov 20172:00 pmRNSPrice Monitoring Extension
13th Nov 201711:05 amRNSSecond Price Monitoring Extn
13th Nov 201711:00 amRNSPrice Monitoring Extension
13th Nov 20179:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.